sector medic suppli devic
 solid quarter fx tax continu
messag sale top consensu ep beat
full howev impress perform appear first glanc nearli
upsid attribut fx tax expens currenc also
main factor behind manag full-year guidanc rais someth note
like preview see strip away nois see quarter step
right direct partial off-set step backward csi overal
view fundament outlook go forward larg unchang
ceo transit smooth one conjunct releas cooper
announc ceo bob weiss retir stint helm
compani year overal mr weiss succeed cfo
chief strategi offic al white longtim execut someon
well known street expect smooth transit would anticip major
strateg shift mr white tenur get underway
currenc gift keep give revenu
pro forma top consensu adjust ep come
street note howev bulk upsid driven
fx lower expect tax rate expens contribut well currenc
boost ep forecast meanwhil combin
lower tax expens ad anoth full year fx expect
add bottom line previous account entireti
manag guidanc rais
estim tax suspens medic devic excis tax provid addit
earn cushion partial off-set higher interest expens
addit reinvest busi exclud currenc paragard accret
estim revis outlook impli underli ep growth
coopervis sale organ came consensu
upsid driven primarili out-performance non single-us sphere
cc toric cc multifoc cc also contribut
beat partial off-set shortfal single-us sphere categori
cc geograph standpoint asia pacif cc bright
spot continu recent string strong perform meanwhil emea cc
acceler soft yoy comp america growth remain sluggish
improv balanc year comp eas estim silicon
hydrogel len sale rose forecast driven robust gain
daili sih franchis cc extend wear side biofin avaira
combin post growth ex-fx solid biofin gain partial off-set declin
avaira sale due on-going vital transit manag rais
revenu guidanc pro forma
disappoint view quarter perform step right
direct estim global contact len sale rose cc calendar
slight drop gain seen first nine month year full
year global sale rose repres modest acceler
grew busi faster market past year math
repres much narrow margin out-performance compani
averag manag believ compress larg result
competitor increas success drive trade-up within instal base
dynam result improv dollar share without actual take share patient
level may part stori sens competit environ
also tougher time continu page
page analyst certif import disclosur
estim compani market share yoy
calendar also share gainer sequenti meanwhil bausch
alcon lost ground vs continu see
construct outlook contact len market go forward driven on-going
penetr higher price silicon hydrogel lens modal mix shift toward daili
along line daili lens account world-wide contact len revenu
calendar year ago period
elsewher genet test weigh coopersurg revenu
pro forma come consensu modest beat
office/surg product pro forma off-set fertil side
busi cc miss street estim driven
declin genet test segment due competit price pressur
dynam expect persist throughout year meanwhil recent acquir paragard
contribut sale expect due account chang relat
reclassif certain distribut expens contra-revenu result
manag expect paragard revenu come
previou forecast despit weaker top line outlook financi impact
paragard readili appar csi gross margin jump nearli yoy
longer term remain optimist paragard non-hormon iud
 market solid contributor especi follow new
england journal medicin studi releas decemb link hormon contracept
higher risk breast cancer view manag decis begin build
dedic sale forc market paragard sign see enhanc upsid case
product well near-term howev issu fertil side
busi like outweigh benefit initi manag lower
csi guidanc pro forma
top line fx lower tax rate boost earn fiscal gross
margin came consensu sg spend rose yoy
sale came street expect meanwhil spend
grew yoy sale match consensu collect result fiscal
ebita margin yoy street estim
margin strong howev currenc drove bottom line beat ad
ep vs expect meanwhil combin lower
expect expens tax rate ad anoth earn math
step right direct wed like see sound
clear lens model call ep total revenu
pro forma compar prior forecast
respect number continu rise past nine
month market larg discount fx-driven ep upsid expect
dynam persist import stock view growth
compani post quarter sustain level perform go forward would go
long way toward address concern competit landscap lens
could believ eventu drive multipl expans point howev havent
seen enough evid fulli put worri rest long-term continu see
top bottom line grower outlook larg reflect
stock current level view maintain neutral rate
page analyst certif import disclosur
straddl line healthcar consum product contact
len women health busi coopervis portfolio uniqu posit take
advantag two tailwind drive contact len market growth today shift
premium len materi particular silicon hydrogel increas popular
daili dispos lens recent year leverag broadest daili sih
offer market lead posit monthli sih categori continu
long histori above-market growth compani captur averag
market share per year sinc expect gain moder go forward
backdrop competit contact len market believ cooper
remain well posit sustain growth
elsewher paragard deal add scale coopersurg grow women health
presenc often overlook investor expect csi account
overal revenu growth fuel
primarili compani invest half dozen deal
build lead posit ivf genet test market follow recent
acquisit paragard intrauterin devic believ long-term
fundament market appeal see grow scale csi neg
broader invest case complic stori believ
investor would prefer look sole contact len play
dust settl paragard see sustain top
grower outlook believ fulli reflect stock current level
limit near-term potenti multipl expans view prefer wait better
entri point consid becom posit stock
valu primarili price-to-earnings basi use repres group mid-cap
med-tech name similar growth characterist comp base guggenheim
factset consensu estim group current trade ntm ep
ebitda repres modest premium price-to-earnings ebitda
multipl valuat see fair result assign share neutral
upsid risk rate includ faster expect contact len market growth due
rise sih penetr daili len adopt increas share gain
busi better expect growth/accret paragard
downsid risk rate includ better anticip traction competit
contact len launch weaken macroeconom backdrop put pressur
cooper busi see discretionari med-tech market
potenti exposur tax reform rise interest rate
page analyst certif import disclosur
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
